In addition, Gan G et al. (93) advocated that SBRT for all oligometastatic foci in NSCLC patients with ALK rearrangement when the disease progressed during the treatment with crizotinib, reporting no grade 3-5 toxicity and a median, one-year, and two-year OS were 39 months, 86%, and 57%, respectively. The gene discussed is ALK; the disease is non-small cell lung carcinoma.